Amgen Inc. (AMGN) PT Lowered to $172.00
The firm presently has a "neutral" rating on the medical research company's stock. Citigroup Inc.'s target price points to a potential upside of 1.35% from the stock's current price.
from Biotech News
The firm presently has a "neutral" rating on the medical research company's stock. Citigroup Inc.'s target price points to a potential upside of 1.35% from the stock's current price.
The most important thing is to improve and not stop. Even if you have taken some course, this does not mean that you are now a guru. You need to constantly practice, learn something new.
0 Comments